3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
176
Neoplasms
173
Carcinoma, Non-Small-Cell Lung
152
Prostatic Neoplasms
108
Colorectal Neoplasms
105
Lung Neoplasms
91
Ovarian Neoplasms
82
Neoplasm Metastasis
76
Multiple Myeloma
72
Pancreatic Neoplasms
70
Leukemia, Myeloid, Acute
63
Endometrial Neoplasms
49
Squamous Cell Carcinoma of Head and Neck
47
Stomach Neoplasms
45
Melanoma
44
Lymphoma
44
Glioblastoma
42
Carcinoma, Renal Cell
42
Recurrence
41
Brain Neoplasms
41
Urinary Bladder Neoplasms
39
Carcinoma, Hepatocellular
39
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Sarcoma
37
Glioma
36
Lymphoma, Non-Hodgkin
35
Hematologic Neoplasms
35
Leukemia, Lymphocytic, Chronic, B-Cell
34
Esophageal Neoplasms
33
Small Cell Lung Carcinoma
31
Interventions
sacituzumab govitecan
1
amrubicin
1
Topotecan
1
PM 01183
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
×
30 days
×
Clear all
NCT06801834
2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3
Recruiting
695 enrolled